SAB Biotherapeutics 2023 Annual R&D Day

Eddie J. Sullivan, PhD, is Co-Founder and has served as President and CEO since 2014. Dr. Sullivan has served in biopharma leadership positions for more than 25 years. Prior to joining SAB, he held the CEO role or other leadership roles in our predecessor entities, including CEO of Hematech, a subsidiary of Kyowa Hakko Kirin. During that time, he led initiatives to develop infectious disease, cancer, and autoimmune immunotherapies. In addition to raising over $250 million in capital to develop biopharmaceutical platform technologies, he has also led several successful mergers and acquisitions. A recognized thought leader in antibodies and transgenic animals, Dr. Sullivan serves on the board of directors for the Biotechnology Innovation Organization (BIO) and has served on its executive committee. He has worked with industry committees and discussion groups that have focused on animal biotechnology, regulatory framework, human immunotherapies, and global health threats. Dr. Sullivan was governor-appointed to South Dakota’s Research Commercialization Council and was Chairman of the state’s National Science Foundation-EPSCoR committee for 12 years. He also founded, served as president, and remains an advisor to the state affiliate of BIO, South Dakota Biotech. Dr. Sullivan earned two PhD’s in Health Science Administration and Reproductive Physiology from Kennedy Western University and Utah State University, respectively. In addition, he holds an MS in Reproductive Physiology and Molecular Biology from Brigham Young University and a BS in Animal Health Sciences from the University of Arizona.

Christoph Bausch, PhD, MBA, is EVP & Chief Operating Officer as of May 2022, overseeing all Research & Manufacturing operations of the company. Prior to his role as COO, he served as Chief Science Officer since joining SAB in April 2017, providing leadership in all areas of Research & Development, and functioned as drug development lead for a Stage 3 clinically advanced drug product. Dr. Bausch is an experienced research scientist, biotech entrepreneur and business development executive who has led the successful discovery, development, biomanufacturing, and commercialization of platform technologies in the life sciences. Previously, Dr. Bausch has served as founder and director of a molecular diagnostic company and has provided life science consulting for Keion Group, LLC. Dr. Bausch held several science-based business development positions prior to joining SAB, most recently for multi-billion-dollar global industrial biomanufacturing leader POET, LLC, where he structured strategic partnerships, prospected, and vetted new technologies and streamlined research and development activities. He also worked in both research and commercialization roles for Fortune 500 life science and high technology company Sigma-Aldrich, now MilliporeSigma. Dr. Bausch currently serves on the Board of Directors for the state affiliate of BIO, South Dakota Biotech, since 2017. He received his PhD in Microbiology at The Ohio State University, Columbus, Ohio, completed Post-Doctoral Training at the Stowers Institute for Medical Research, Kansas City, Missouri and earned an MBA from St. Louis University, St. Louis, Missouri, in addition to a BA in Biology from the University of Nebraska-Lincoln, Lincoln, Nebraska.

Alexandra Kropotova, MD, MBA is EVP & Chief Medical Officer, joining SAB in June, 2022 to lead the strategy, direction, and execution of the company’s clinical development for the entire portfolio. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Prior to joining SAb Biotherapeutics, as a Therapeutic Area Head of Global Specialty R&D at Teva Pharmaceuticals, Alexandra led innovative drug development focused on delivering a broad portfolio of immunology, respiratory, and immuno-oncology assets spanning from pre-IND to BLA/NDA filing of biologics and complex drug-device combination products. Prior to Teva, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D Clinical Development; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. She also served in various roles at Pfizer Inc., most recently as Director & Head of Global Clinical Respiratory and Analgesics. She continues to serve on the Board of Directors at iBio, a global leader in plant-based biologics manufacturing and development of novel biopharmaceuticals. Dr. Kropotova received her MBA from Ohio University Graduate School of Business, Athens, Ohio; and her M.D. in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia.

Dr. Michael Haller is a pediatric endocrinologist with a passion for patient care, teaching, and research. Mike is a Gainesville native and a proud graduate of the University of Florida’s College of Medicine, Pediatrics Residency, and Pediatric Endocrinology Fellowship Programs. In addition to serving as the Pediatric Endocrinology Chief and Fellowship director, Dr. Haller coordinates an active research team focused on the prediction, prevention, and reversal of type 1 diabetes. Dr. Haller is an active investigator in the NIH funded Type 1 Diabetes TrialNet, the NIH TEDDY study, and the T1D Exchange. Mike serves as the PI of the University of Florida TrialNet Clinical Center, as the Chair of the Clinical Implementation Committee for the TEDDY study, and as Vice-President of the Florida Camp for Children and Youth with Diabetes. Dr. Haller was the PI of “first in man” studies aimed at using autologous umbilical cord blood stem cells as a potential therapy for type 1 diabetes and more recently led a groundbreaking pilot study demonstrating the efficacy of Thymogloublin and Neulasta in patients with established type 1 diabetes. Dr. Haller served as the PI of a major TrialNet study that confirmed the efficacy of low-dose Thymoglobulin in new-onset type 1 diabetes patients. Dr. Haller has published over 200 peer reviewed manuscripts and book chapters and in the last 5 years has received over $10 million dollars in research funding. Mike has received the Henry Kokomor award, the Douglas Barrett award, the Pediatric Endocrine Society Clinical Scholar award, and the JDRF Early Career award. In 2008, Dr. Haller, and his colleagues Dr. Desmond Schatz and Dr. Mark Atkinson received the JDRF’s highest award, the Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award, for their team approach to developing therapies for type 1 diabetes. In 2016, Dr. Haller took the reins from his long time mentor Dr. Janet Silverstein to become the Division Chief of the Pediatric Endocrinology Division at the University of Florida. In 2017, Dr. Haller was awarded both a UF Term Professorship and the prestigious UF Research Foundation Professorship.